Investors indulged in profit booking at attractive and higher valuations
While companies continue to face regulatory pressure leading to higher costs, they see an uptick from the launch of differentiated and high-margin products
Among the companies likely to sign deals with Gilead are Cadila, Hetero, Strides Arcolab and Mylan, while Cipla is expected to earn active pharmaceutical ingredient rights.
Dr Reddy's, Glenmark, Wockhardt have lined up alternatives for Zytiga
The antiviral drug may cost around Rs 55,000 for an 11-dose course, or Rs 5,000 per injection -- much less than the price of imports from Bangladesh, reports Sohini Das.
US firm Mylan NV received a stern warning from the FDA in August for faulty manufacturing practices at three of its India drugmaking plants.
The challenge of merging Ranbaxy into the company has not been factored in.
The FIPB, headed by Department of Economic Affairs Secretary Arvind Mayaram, discussed 30 foreign direct investment proposals, including 10 from pharma sector.
The government has approved 16 projects envisaging foreign investment worth Rs 1,647 crore (Rs 16.47 billion), while deferring Punj Lloyd's proposals for lack of security clearance.
FDI in drugs and pharmaceuticals was $487 million during April-August 2012, according to the latest data of the Department of Industrial Policy and Promotion.
The Singapore subsidiary of the UK-based GlaxoSmithKline plans to buy 24.33 per cent stake or 2.06 crore equity shares in GlaxoSmithKline Pharmaceuticals Ltd through an open offer.
GVK Biosciences is the latest Indian firm to come under international scrutiny over quality issues.
Drugs under exemption make up roughly 95 per cent of the antiretrovirals used by India's AIDS patients
The founders of Gland Pharma, led by Ravi Penmetsa, and KKR, together own 96 per cent of the company.
Indian pharma firms under European drug regulator's scanner.
The Ranbaxy experience has made multinational corporations more cautious about Indian acquisitions in general
Unlike India, the US is a free-pricing market.
FDI in brownfield investment has resulted in acquisition of domestic drug-manufacturing firms by multinational companies.
.jpg)
According to information available on the European Commission website, Ranbaxy Laboratories has been fined euro 10.32 million (over Rs 80 crore).
The finance ministry is resisting pressure from other departments to cap foreign ownership of domestic drugmakers, fearing such a move would discourage potential investors, a senior ministry source said.
The benchmark Nifty rallied 1,000 points or 17% from 7,000 in 78 trading sessions since May 12, till date to surpass the 8,000 mark.
Indian firm to soon launch copycat of anti-breast-cancer drug.
The number of small units has come down drastically, as large companies have expanded their manufacturing capacity.
More, many market gurus expect the Sensex to reach 30,000 levels by December and 40,000-45,000 in three to four years.
Even smaller companies like Torrent Pharma and Alembic file five to 10 ANDAs every year.
The 30-share Sensex ended 50 points lower at 28,112 and the 50-share Nifty declined 12 points to close at 8,531.
Sensex is under pressure due to concerns in the global market.
Details on prices sought as 10 generic drugs become up to 83 times costlier in 6 months
It's time for Indian generic companies to rethink their strategies.
FDA inspectors visited the Mohali plant in the process of giving approval to Ranbaxy's application for Valsartan.
'Pay-for-delay' settlements between drug patent-holders and generics manufacturers to delay the launch of cheaper generic medicine are increasingly being scrutinised by antitrust regulators
Import alert on Ranbaxy's Mohali unit; Strides' injectible arm gets warning letter
The India Abroad Person of the Year Awards, held at the National Museum of the American Indian in New York City on Friday June 12, honored 14 achievers in seven categories.
In a surprise announcement in April, Sun and Ranbaxy -- at that time owned by Japan's Daiichi -- declared an all-stock deal to create India's largest and world's fifth-largest drugmaker in an over $4 billion deal.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances